Glucagon vs Glucose: In-depth Analysis of Peptide Product Composition
Abstract: This in-depth analysis compares glucagon and glucose as peptide-based products for hypoglycemia management. Glucagon, a 29-amino acid peptide, offers rapid glycemic correction via injection, while glucose provides immediate oral or intravenous action. Market trends show a shift toward stable, room-temperature glucagon formulations (e.g., nasal powder, ready-to-use pens), driven by patient convenience and safety. Key product parameters include stability (glucagon’s susceptibility to aggregation vs. glucose’s chemical stability), half-life (glucagon 18 min vs. glucose immediate), and regulatory certifications (FDA, EMA, GMP). Brand comparisons (e.g., Baqsimi vs. Glucagon Emergency Kit) highlight delivery system advantages. Industry data indicates glucagon’s growing dominance in emergency care, while glucose remains first-line for mild cases. Selection criteria prioritize formulation stability, storage logistics, and certification compliance.